Zydus receives approval from DCGI for Saroglitazar Magnesium for treatment of Type II Diabetes


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Zydus
Zydus’ Saroglitazar Magnesium has been approved for the treatment of diabetes mellitus type 2 by the Drug Controller General of India

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has received the approval from the Drug Controller General of India for use of Saroglitazar Mg in the treatment of Type II Diabetes Mellitus as an add on therapy with Metformin. The drug was previously approved in the year 2013 for the treatment of ypertriglyceridemia and Diabetic Dyslipidemia in India. More than 1 Million patients are being treated with LipaglynTM.

The Diabetes Phase 3 clinical trial was a Multi-centric, Prospective, Randomized, Double- blind Study to Evaluate the Safety and Efficacy of Saroglitazar Mg 2 mg and 4 mg as compared to Pioglitazone 30 mg in patients with type 2 diabetes. The Phase 3 trial conducted in 1140 type 2 diabetes patients for a total of 56 weeks met the primary end-points (CTRI/2015/09/006203). The primary outcome measure was the change from baseline in glycosylated hemoglobin (HbA1c) for Saroglitazar 4 mg, 2 mg and Pioglitazone 30 mg at 24 weeks. The secondary outcome measures hange from baseline in fasting plasma glucose, 2 hour postprandial plasma glucose, lipid profile, Triglyceride (TG) cholesterol, Low density lipoprotein (LDL) cholesterol, Very low density lipoprotein (VLDL) cholesterol, High density lipoprotein (LDL) cholesterol, Total cholesterol (TC) cholesterol, Non HDL cholesterol, Apolipoprotein (Apo) A1 and Apo B between Saroglitazar (4 mg, 2 mg) and Pioglitazone (30 mg) treatment at Week 12, 24 and 56.


In Phase III diabetes trial, at 24 weeks, HbA1c was reduced by 1.38 g/dL with Saroglitazar 2 mg, 1.47 g/dL with Saroglitazar 4 mg and 1.41 g/dL with Pioglitazone 30 mg. At 56 weeks, HbA1c reduced by 1.34 g/dL with Saroglitazar 2 mg, 1.49 g/dL with Saroglitazar 4 mg and 1.47 g/dL with Pioglitazone 30 mg. Saroglitazar did not cause ypoglycemia or weight gain in this trial.


“Insulin resistance is one of the primary causes of diabetes and there is a huge unmet medical need for a safe and effective insulin sensitizer. Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from Type 2 diabetes mellitus. With the increasing cases of diabetes in India, the need to strengthen diabetes management and help patients control their blood sugar levels is of critical importance.” mentioned Pankaj Patel, Chairman, Zydus Group.

Saroglitazar (Lipaglyn™), is a novel PPARα/γ agonist having predominant PPAR alpha activity. The recommended dose of Lipaglyn™ is 4 mg once-a-day. Lipaglyn™ is a prescription drug and should be taken under guidance of a registered medical practitioner. Lipalgyn™ was first launched in India during September 2013. Over the last several years, more than 1 Million patients have been treated with Lipaglyn™ in India for management of Hypertriglyceridemia and Diabetic Dyslipidemia, and data has been presented at several scientific and medical conferences.

Tags : #Zydus #Type2diabetes #Drug #Controller #General #India #Medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026